<code id='43C9596B23'></code><style id='43C9596B23'></style>
    • <acronym id='43C9596B23'></acronym>
      <center id='43C9596B23'><center id='43C9596B23'><tfoot id='43C9596B23'></tfoot></center><abbr id='43C9596B23'><dir id='43C9596B23'><tfoot id='43C9596B23'></tfoot><noframes id='43C9596B23'>

    • <optgroup id='43C9596B23'><strike id='43C9596B23'><sup id='43C9596B23'></sup></strike><code id='43C9596B23'></code></optgroup>
        1. <b id='43C9596B23'><label id='43C9596B23'><select id='43C9596B23'><dt id='43C9596B23'><span id='43C9596B23'></span></dt></select></label></b><u id='43C9596B23'></u>
          <i id='43C9596B23'><strike id='43C9596B23'><tt id='43C9596B23'><pre id='43C9596B23'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:85
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Kellogg’s is going to war over Mexico’s nutrition label rules
          Kellogg’s is going to war over Mexico’s nutrition label rules

          AlexHogan/STATMEXICOCITY—Kellogg’siswagingawarhereoverTigreToñoandSamelTucán.A2019policyrequirescomp

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Abortion policy in the spotlight at Republican debate

          AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis.Signupheretoreceivethisnewsletterinyourinbox